Amyotrophic Lateral Sclerosis: Radicava and Riluzole’s Impact
Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative disease, causes the deterioration of motor neurons, leading to muscle weakness, loss of motor function, and eventually respiratory failure. With a growing prevalence of amyotrophic lateral sclerosis worldwide, treatment options have become an area of intense research. Among the FDA-approved drugs for ALS, Radicava (edaravone) and Riluzole are two notable therapies offering hope to those battling the disease.
The Role of Radicava (Edaravone) in ALS Treatment
In 2017, the FDA approved Radicava (edaravone), a significant milestone in ALS treatment. Radicava works by reducing oxidative stress, a key factor that accelerates the progression of ALS. Its approval marked a breakthrough for patients who had limited treatment options. Clinical trials have shown that edaravone can slow the decline of physical function, offering patients a higher quality of life for a longer period.
While Radicava does not cure ALS, it represents one of the few FDA-approved drugs for ALS that targets the disease's underlying mechanisms. It is typically administered through intravenous infusions, making its treatment regimen unique and requiring regular medical visits.
The Legacy of Riluzole in ALS Care
Riluzole, the first FDA-approved drug for ALS, has been in use since 1995. Riluzole works by inhibiting the release of glutamate, an excitatory neurotransmitter that can cause motor neuron damage when present in excess. While it does not reverse the damage already done by ALS, it has been shown to modestly extend survival and delay the progression of symptoms.
Over the years, various formulations of Riluzole have been introduced, including an oral tablet and an oral suspension. Despite its limited effect in halting ALS's progression, Riluzole remains a cornerstone of ALS treatment.
Conclusion
While the search for a cure for ALS continues, drugs like Radicava and Riluzole provide essential support in managing the disease. With ongoing advancements in research, the future of ALS treatment holds promise for improved therapies that can offer better outcomes for those living with ALS.
Latest Reports:
Leukocyte Adhesion Deficiency Market | Life Science Business Development | Life Science Consulting | Lymphedema Market | Mallory-weiss Tear Market | Medical Marijuana Market | Mismatch Repair Deficiency Market | Molecular Glue Market | Natural Killer Nk -cell Lymphoma Market | Nerve Sheath Neoplasms Market | Net Market | Neuroleptic Malignant Syndrome Market | Ntm Market | Oncocytoma Market | Ophthalmoplegia Market | Wide Neck Bifurcation Intracranial Aneurysms Market | Phosphoglucomutase Pgm 1 Deficiency Market | Plague Market | Point Of Care Glucose Testing Market | Polypoidal Choroidal Vasculopathy Market | Primary Gastric Lymphoma Market | Research Subscription | Ringworm Market | Scabies Market | Wolman Disease Market | Subscription Healthcare | Wound Irrigation Systems Market | Trastuzuma Biosimilar
English
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian